Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T18:28:11.430Z.
Calculation as of: 2026-10-06T18:28:11.430Z.
Quote observation: 2026-10-06T18:25:06.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6f5be79ac0e7715def3f298c248b41853c7a510be646acbaec4ce361b11b20d4
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$23.84M
EV/Sales Ratio
6.18x
TTM Avg
7.13x
3Y Avg
10.91x
5Y Avg
8.82x
Market Cap
$21.68M
EV/Sales Ratio
0.23x
TTM Avg
0.37x
3Y Avg
0.25x
5Y Avg
0.21x
Market Cap
$24.18M
EV/Sales Ratio
N/A
TTM Avg
8660.16x
3Y Avg
2951.18x
5Y Avg
1830.92x
Market Cap
$20.99M
EV/Sales Ratio
N/A
TTM Avg
207.31x
3Y Avg
4938.40x
5Y Avg
4938.40x
Market Cap
$25.24M
EV/Sales Ratio
N/A
TTM Avg
390.99x
3Y Avg
224.70x
5Y Avg
223.08x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Rein Therapeutics Inc. (RNTX) | $22.88M | N/A | N/A | N/A | N/A |
| TherapeuticsMD, Inc. (TXMD)vs › | $23.84M | 6.18x | 7.13x | 10.91x | 8.82x |
| LeonaBio, Inc. (LONA)vs › | $22.56M | N/A | N/A | N/A | N/A |
| Modular Medical, Inc. (MODD)vs › | $21.84M | N/A | N/A | N/A | N/A |
| Kyntra Bio, Inc. (KYNB)vs › | $23.92M | N/A | 1.44x | 1.04x | 4.23x |
| Aytu BioPharma, Inc. (AYTU)vs › | $21.68M | 0.23x | 0.37x | 0.25x | 0.21x |
| ABVC BioPharma, Inc. (ABVC)vs › | $24.18M | N/A | 8660.16x | 2951.18x | 1830.92x |
| Quantum BioPharma Ltd. (QNTM)vs › | $20.99M | N/A | 207.31x | 4938.40x | 4938.40x |
| Atossa Therapeutics, Inc. (ATOS)vs › | $25.24M | N/A | 390.99x | 224.70x | 223.08x |
| InspireMD, Inc. (NSPR)vs › | $25.30M | 1.12x | 8.15x | 11.91x | 8.44x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
